Sign in
STOK Stock Price, Chart, Stats & News
Stoke Therapeutics Inc
Save
Stoke Therapeutics Inc (STOK) does not currently pay a dividend.
1.83B
Market cap
–
Current P/E
204.08x
Forward P/E
STOK chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | 98.89% |
Operating margin | -11.16% |
Pretax margin | -3.73% |
Net margin | -3.73% |
Effective tax rate | – |
ROA | -1.65% |
ROE | -2.05% |
D/E | – |
Interest coverage ratio | -3431.67x |
STOK valuation
P/E | – |
P/S | 10.54x |
P/B | 5.44x |
P/CF | 42.08x |
P/FCF | 43.26x |
P/OCF | 42.08x |
PEG | 2.48x |
EV multiple | -143.23x |
About
Stoke Therapeutics, Inc. is an emerging biopharmaceutical company dedicated to developing innovative antisense oligonucleotide (ASO) therapies. Its primary focus is to target and address the fundamental causes of severe genetic disorders, particularly within the United States. The company employs its exclusive Targeted Augmentation of Nuclear Gene Output (TANGO) platform to engineer ASOs that precisely enhance protein expression.
Similar securities
Based on sector and market capitalization
Report issue